MSD hit with €39m fine over contraceptive generic delay

The probe in Spain centred on the delayed entry of generic versions of a branded contraceptive | The commission found evidence of “unjustified legal action”.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

MSD prevails in diabetes drug dispute with Mylan

29 September 2022 MSD, known as Merck in the US and Canada, has won against a case concerning branded diabetes treatment Janumet XR at the US Court of Appeals for the Federal Circuit.

Americas

MSD makes $1.4bn bid on biopharma company

22 November 2022 Move could garner ‘milestone’ treatment for one of MSD’s portfolios | Activity comes after a Spanish watchdog fined the pharma firm $39 million.

Americas

MSD accuses university of patent contract breach

1 December 2022 Ex-partners collaborated on a clinical study for a cancer treatment | Pharma firm insists that it has exclusive licensing rights | MSD | John Hopkins.

More on this story

Big Pharma

MSD prevails in diabetes drug dispute with Mylan

29 September 2022 MSD, known as Merck in the US and Canada, has won against a case concerning branded diabetes treatment Janumet XR at the US Court of Appeals for the Federal Circuit.

Americas

MSD makes $1.4bn bid on biopharma company

22 November 2022 Move could garner ‘milestone’ treatment for one of MSD’s portfolios | Activity comes after a Spanish watchdog fined the pharma firm $39 million.

Americas

MSD accuses university of patent contract breach

1 December 2022 Ex-partners collaborated on a clinical study for a cancer treatment | Pharma firm insists that it has exclusive licensing rights | MSD | John Hopkins.

More on this story

Big Pharma

MSD prevails in diabetes drug dispute with Mylan

29 September 2022 MSD, known as Merck in the US and Canada, has won against a case concerning branded diabetes treatment Janumet XR at the US Court of Appeals for the Federal Circuit.

Americas

MSD makes $1.4bn bid on biopharma company

22 November 2022 Move could garner ‘milestone’ treatment for one of MSD’s portfolios | Activity comes after a Spanish watchdog fined the pharma firm $39 million.

Americas

MSD accuses university of patent contract breach

1 December 2022 Ex-partners collaborated on a clinical study for a cancer treatment | Pharma firm insists that it has exclusive licensing rights | MSD | John Hopkins.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent

MSD hit with €39m fine over contraceptive generic delay

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features